Abstract 1638P
Background
FOLFIRINOX and gemcitabine-nabpaclitaxel (GnP) are both standard first-line treatment regimens for advanced pancreatic ductal adenocarcinoma (PDAC), however, predictive biomarkers are currently lacking to guide treatment selection. We aimed to investigate the prognostic and predictive value of class III β-Tubulin (TUBB3) and human equilibrative nucleoside transporter 1 (hENT1) expression, which have previously been shown to be associated with taxane and gemcitabine resistance in advanced PDAC.
Methods
We conducted a retrospective analysis of 106 patients with advanced PDAC at Hacettepe University Cancer Institute. TUBB3 and hENT1 immunohistochemical staining were analyzed in tumor specimens and scored jointly according to the intensity of expression: high score (TUBB3low/hENT1high) and low score (TUBB3high/hENT1high, TUBB3low/hENT1low or TUBB3high/hENT1low). Response rates and progression-free survival (PFS) rates were compared based on TUBB3 and hENT1 expression.
Results
The median age was 60 years (range; 38-80 years) and 65% were male patients. The median progression-free survival (PFS) and overall survival (OS) of patients were 6.83 and 12.06 months, respectively. In patients who received the GnP regimen (n=68), a high combined score (TUBB3low/hENT1high) was associated with a higher disease control rate (DCR) (84.2% vs. 39.6%, p=0.001) and longer PFS (8.76 months vs. 3.1 months, p<0.001) compared to those with low score. In the multivariate analysis, a high combined score was an independent predictor of higher DCR (OR: 11.96; 95% CI: 2.61-54.82; p=0.001) and longer PFS (HR: 0.33; 95%CI: 0.18–0.60; p<0.001). However, there was no difference in response rates or PFS based on TUBB3 and hENT1 expression among patients receiving FOLFIRINOX regimen.
Conclusions
Our findings suggest that tumor TUBB3 and hENT1 expression may predict the efficacy of GnP regimen, and low TUBB3 and high hENT1 expression are associated with a higher DCR and longer PFS in patients with advanced PDAC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22